Immunology Company Kira Biotech launches with A$20M Series A Funding
Related Articles
-
Arrow / HCC PhD scholarship recipient is closer to discovering a new treatment option
Featured in the Arrow Newsletter, Issue 2, 2015. Michael Papadimitrious, from Dendritic Cell Research, prepares his first paper. Michael is...
-
Global leader predicted for medical research
Featured in Burwood Scene, June 18, 2014. TREASURER Joe Hockey has declared that Australia will become a global leader...
-
Dr Silveira presents at The Transplantation Society Conference
On my way to The Transplantation Society (TTS) conference in Spain, I stopped off in Oxford UK, where I...
-
The First Ladies
Featured in Burwood Scene, August 7, 2013. The Inner west will be well served by four full-time working women as...
-
Balmain doctor’s short solution for cancer
Featured in Burwood Scene, July 3, 2015. Balmain haematologist Christian Bryant knows just how important it is to keep...
-
2015 – What a Year for DCR!
2015 has been a great year for Dendritic Cell Research. DC Down Under 2015 was another great success. With...
-
Government supports blood cancer research
Featured in ANZAC Institute Discovery, May 2012. The NSW Government has awarded $3.47 million over 5 years in a...
-
Bendigo Bank Supports ANZAC Research Institute Research Fight for Leukaemia
The Dendritic Cell Biology and Therapeutics Group (DCBTG) at the ANZAC Research Institute is a specialized facility focused on...
![](mailto:?subject=Immunology Company Kira Biotech launches with A$20M Series A Funding&body=
<img class="aligncenter wp-image-3224 size-medium" src="http://dcresearch.org.au/wp-content/uploads/2019/10/Kira-Biotech-logo-300x150.jpg" alt="" width="300" height="150" /><br />
Brisbane, 29 October 2019: Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders.
The round was led by OneVentures, with significant investment from IP Group and support from the Advance Queensland Business Development Fund. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies. <a style="color: #ffcc00;" href="https://kirabiotech.com/wp-content/uploads/2019/10/20191024-Kira-Biotech-Series-A-funding-press-release.pdf">Read More</a>
http://dcresearch.org.au/immunology-company-kira-biotech-launches-with-a20m-series-a-funding/){kind=link}